A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Metastatic Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jan 2025, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 1/2
- Patients
- 245 (final count)
- Started
- Dec 28, 2020
- Main results expected
- Jan 31, 2025
- Fully finished
- Jan 31, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of adverse events (AEs)- Part 1
Measured over: Up to follow-up period, approximately 53 months
Occurrence of serious adverse events (SAEs)- Part 1
Measured over: Up to follow-up period, approximately 53 months
Occurrence of adverse events (AEs)- Part 2
Measured over: Up to follow-up period, approximately 53 months
Occurrence of serious adverse events (SAEs)- Part 2
Measured over: Up to follow-up period, approximately 53 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-01-31, no fading
Raw record changes
- none yet
Trial ID NCT04538742 · record last updated 2025-12-08 · checked 2026-11-09 15:47 UTC